Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus Bortezomib vs Rituximab in Newly Diagnosed ITP
NCT03443570Phase 3Unknown
- Sponsor
- Shandong University
- Start
- Mar 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in immune thrombocytopenia (ITP), sponsored by Shandong University. Status: unknown.
02
Drugs
bortezomib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03443570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443570.